Corporate News Releases

Review Article, Authored by ZyVersa Therapeutics' Esteemed Scientific Advisors, Demonstrates the Role of Inflammasomes in the Exacerbated Immune Response Associated with COVID-19 Infection (Just Published in Frontiers in Immunology)
Journal of Neuroinflammation Article Highlights the Role of Inflammasomes in the Pathogenesis of Multiple Sclerosis, and Mentions the Potential for ASC Inhibitor, IC 100, to Interfere with Inflammasome Signaling at Multiple Points in the Inflammatory Pathway
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases
ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020
Business Worldwide Magazine Names ZyVersa Therapeutics in Twenty Most Innovative Companies to Watch
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2019 Healthcare Conference
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019
ZyVersa Therapeutics' Viewpoint on "Why Kidney Indications Are Coming into Sharp Focus" Reported in BIOCENTURY Innovations' Article